Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Last Day to Save at Digital RESI March 2022

17 Feb

By Antoinette Lowre, Manager of Business Development, LSN

Tomorrow is the final day to save! On Friday, February 18, Digital RESI March early bird rates come to an end, making it the last day to save $200 on registration.

The Redefining Early Stage Investments (RESI) conference series connects startups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development over three days. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare. Register here to sign up and save!

In addition to one-to-one meetings, one of our most popular events is the Innovator’s Pitch Challenge (IPC). The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Applications are open and accepted on a rolling basis, so get yours in today!

To learn more about Digital RESI March check out our brochure! We hope to see you there!

resi-march-2022

Help! How to Connect When an Investor Won’t Respond

17 Feb

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN) is well-known for teaching startup founders how to identify fit, reach out, and follow up with early-stage investors, but a prominent issue remaining is this: What happens when the message is clear, the materials are strong, the fit is promising, but you cannot get a response? What happens when an investor ghosts you?

Let’s go back to the beginning: No outreach campaign should consist of just one message. When working with our clients, we always recommend crafting a four-part outreach plan. The first message, which should be your elevator pitch, should be followed by several other messages, each highlighting a different part of the company that makes you unique. Whether this is the management team, a KOL in your advisory board, a strategic partnership that will help your technology enter the market – the messages will depend on what makes your company unique. Make sure to wait a decent interval between your outreach attempts, as you do not want the investors to feel that you are overloading them with messages. Also, do not take the lack of response personally. Many investors liken their inboxes to ‘drinking out of a firehose’ with the sheer number of inbound messages they receive from startups, and they may have just missed the first message.

If you find yourself consistently getting either no or negative feedback, you may need to adjust your messaging. A service, like LSN’s Branding and Messaging, can help craft a message that will resonate. You may also have connections with investors who can help identify what should be adjusted for a better response. One company at a past RESI crafted multiple messages and tried them all just to see which got him the best result. Once he saw which message garnered the most attention, he went forward with that for the rest of his outreach and ended up with an extremely successful conference, with many connections made. When fundraising outside the context of a conference, we recommend waiting with your top-tier targets, specifically to allow you to adjust your messaging to improve the response.

Another way companies can make themselves stand out is by putting in the effort to customize their messages for the investor. Say why you think it is a good fit for them, based on their investment criteria, or mention a specific portfolio company that made you think you would be a good fit for them. Investors can tell when you exert special effort to catch their attention specifically, and that can make them pay more attention to you in turn. While this makes the outreach stage a lot more labor-intensive, the outcome can be worth the effort.

Lastly, be creative in your outreach strategy. Doing an email campaign or requesting a meeting at a partnering conference are obvious choices, but in addition to these, you can find alternative paths to an initial meeting. Social media platforms like LinkedIn can be extremely useful for this – Look for the investor you are trying to reach and see if any unexpected connections pop up that you can utilize to make an introduction. If, when looking through the investor’s portfolio companies, you find one that you know, they may be willing to connect you, as well. Business connections do not always start through an introduction by someone you know extremely well, sometimes an acquaintance will make the connection that matters most – So keep your mind open and keep trying until you succeed!

While these tips can help limit the chance of having messages missed or ignored by investors, there is no fool-proof way to ensure that does not happen to you. It is an inevitability that some messages may go unread or unanswered, even from an investor who seemed initially interested. In this case, your best course of action is to follow the outreach plan outlined above. Trying to understand why or reading into a crystal ball may not be the best use of your time. It is an unfortunate part of the process, which is why fundraising is a numbers game and you increase your odds with every message. Remember that it is not personal, and so long as you are crafting a compelling message with a strong story to the right people, you are heading in the right direction.

Want to learn more? Join us at a free bootcamp: Strategies for Successful Partnering on Tuesday, March 8 at 12PM EST. This bootcamp covers tactical fundraising skills for early-stage companies on how to build a target investor list to prepare investor meetings. Sign up today and learn more about LSN partnering events like Digital RESI, March 22-24. Early bird registration rates end Friday, February 18.

resi-march-2022

Startup ABCs: Academics Becoming CEOs

10 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is the leader in connecting early-stage life science and healthcare startups with capital and licensing deals. While academia remains one of the most powerful institutions for innovative tech, the main challenge we see with the founders is that they are entering into a new business universe, more specifically, a startup business universe. They enter this universe with powerful technology that they hope to translate and commercialize. But first-timers are often lacking the rudimentary skillset to succeed at launching a startup. These often-overlooked aspects, which LSN refers to as the tactical “nuts and bolts,” consist of getting their story straight, identifying partners that fit their stage of development and product, and messaging these potential partners through all the different modalities available today.

The big shift from academic to founder includes a basic understanding of business development, marketing, and sales, all of which are needed to find capital investors, licensing partners, and product collaboration partners. When it comes to partnering, it’s important to understand that the very first step is identifying and curating a list of potential partner profiles that are a fit for the startup’s stage of development and product set. Developing this list is the singular most important step, and it must be done thoroughly. Once this is done, the second and third steps come naturally. The second step is developing a system to track contacts and keep the list updated, and the third consists of outreach and following up. Founders who have completed step one must keep their list organized and in a safe and accessible location (not Excel). I’m talking about a CRM. From here, they can start to curate and track partners. Deals can take anywhere from 9-18 months, from start to finish, and keeping the partner profiles updated and associated tasks and deliverables current. It is imperative to be efficient and organized in running a global partnering campaign.

Through its events, products, and services, LSN has spent the past decade guiding academic innovators and teaching these basic business development concepts and tools that prepare them for their foray into the early-stage startup environment and fundraising. The Valley of Death doesn’t need to be the end of a great idea and LSN is a trusted partner in that process. Contact our business development team to learn more about how our events, products, and services can help connect you to the next step along your early-stage journey.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International East Coast (USA) & China Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development, General Manager Europe
Book a Meeting
Email Me
Candice He
Vice President of Business Development, Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

resi-march-2022

Making a Difference One Impression at a Time

10 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

Amplified Sciences CEO and Co-Founder, Diana Caldwell knows a lot about lasting impressions. It was an early impression working with her co-founder, Dr. Jo Davisson that led her to join him in leading Amplified Sciences and advancing the early detection of devastating diseases, such as pancreatic cancer. Additionally, Diana’s recent first-place win at the Digital RESI JPM Innovator’s Pitch Challenge (IPC) was a result of the impressions she left with judges and attendees alike with marketing materials and a live pitch.

Listen to our conversation to learn more about Diana’s career as a pharma executive and how her experience and passion led her to her latest adventure: entrepreneurship, fundraising, changing the diagnostic landscape, and leaving all the right impressions along the way.

The IPC returns to Digital RESI March 22-24. Apply today and save $200 when you register by February 18!

resi-march-2022

Free Fundraising Bootcamps

10 Feb

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

In our 10 years of experience hosting the Redefining Early Stage Investment (RESI) conference series and curating our Investor Database, Life Science Nation (LSN) has interacted with myriad startup companies, investors and strategic partners, and witnessed many deals come to fruition. This is tremendously rewarding for the team at LSN. It has also given us a lot of insight into the keys to successful fundraising strategies and the tools that really help companies close a round.

Everything we do at LSN is aimed at promoting connections that will lead to companies getting the funding to take their technologies one step closer to helping real people. Our fundraising bootcamp series shares our insights on fundraising so that life science entrepreneurs can be better prepared to find and engage the right investors and strategic partners.

Take advantage of these FREE bootcamps and best of luck in your fundraising endeavors!

Wednesday, February 16, 2PM EST Sign Up
Wednesday, February 23, 2PM EST Sign Up
Tuesday, March 8, 12PM EST Sign Up

resi-march-2022

Hot Investor Mandate: USA-Based Evergreen Fund is Most Interested in Orphan & Rare Disease Therapeutics Investments, Allocating Up to $10M

10 Feb

Atheneos Ventures is a healthcare-focused, evergreen incubator fund based in the San Francisco Bay Area, going forward focusing on orphan drugs and rare diseases via a holding company-fund business model pioneered by the firm in 2009 for common diseases. This new entity is called Atheneos Global, a pathfinder company, focused on orphan diseases is being launched in Q1, 2018. However, the firm collaborates with an affiliate, Spire BioVentures, on projects that are not in the orphan diseases space.

The firm has a very high threshold for working with companies, and makes most of its investments in companies with which there is some type of relationship, but it is open to new opportunities as well on a case-by-case basis. The firm is mainly focused on therapeutics and will consider platform technologies, however only platforms capable of generating drug candidates. The firm’s investment size varies widely depending on the needs of the company, and expected to commit between $5M-$10M for the life of the company (from start to exit). The capital structure depends on the financing round, with convertible notes being preferred for seed rounds and equity for everything else (no debt financing) with the preferred entry point being seed or Series A. Atheneos only co-invests, and does not lead rounds unless the key principals are part of the founding entrepreneurs. The firm has some limitations on geographic exposure and will consider companies in the United States, Canada, Singapore, Spain, the Netherlands, Switzerland or the United Kingdom.

Atheneos will invest in therapeutics (no specific indication) that treats orphan diseases with strong scientific rationale. For Atheneos, not all orphan indications are rare or ultra-rare since the future is fragmentation of common indications characterized thru genomics or proteomics profile. The firm is interested in earlier stage assets and will consider anything from pre-clinical up to Phase IIa. In the past, the firm has invested in therapeutics (a single asset or a company with multiple products), which treat unmet needs in glaucoma, thrombosis (in particular patients with prosthetic heart valves and renal dysfunction), atrial fibrillation, inflammatory disorders (such as ulcerative colitis), gastrointestinal disorders (such as constipation, reflux disease) as well as a small molecule to treat neurovascular disorders such as Alzheimer’s disease, wet-age related macular degeneration. Atheneos will consider early-stage therapeutics to treat orphan disease including small molecules, and novel biologics (including “biobetters”) that are likely to obtain or already have issued composition of matter patents and platform technologies (that could generate novel drug candidates) with least interest in repurposed drugs, biosimilars and cell/gene therapy candidates. The firm at present is not interested in diagnostics, medical devices or digital health but may work thru its affiliate, Spire BioVentures, for projects in this area.

Atheneos does not have any specific management team requirements, and will work with all entrepreneurs. A board seat is not always required, but is not uncommon.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Early Bird Rates at Digital RESI March 2022

3 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI JPM is barely out of the rearview mirror at Life Science Nation (LSN), but that doesn’t mean Digital RESI March isn’t coming up fast. RESI is not meant to be a one-shot success story. It’s designed to follow the principles of early-stage fundraising:

1 It’s a numbers game.
2 It takes time.
3 It requires research, a compelling story, and strategic outreach and follow-up.

RESI returns five times each year, not only as a tool in the shed of investors seeking portfolio assets, but also as a platform for startups to connect, meet, and pitch to investors and strategic partners who are a fit for their product and stage of development. The rapid turnaround of events speaks to the importance of consistency and the speed necessary to progress with partnerships. This also means that the window for early-bird season is coming to a close.

Startups can save $200 when they register for Digital RESI March by February 18. RESI is priced competitively with the understanding that resources are tight while fundraising. Early bird rates invite founders to get involved early to start working with some of LSN’s powerful complimentary resources to enhance their RESI experience and support their outreach. See what Digital RESI JPM attendees have to say and contact us to learn more about our exclusive rates and upcoming free bootcamps to get 2022 fundraising off on the right foot!

“This was our first conference, and we were very pleased with the quality of the companies that we met and with the communications from the conference organizers.”

“I very much appreciate the ability to attend RESI conferences as an investor.”

“I like this platform and helpful LSN folks very much and feel LSN is doing an excellent job creating a friendly community for early-stage startups.”

resi-march-2022